VIVUS is a pharmaceutical company dedicated to improving the quality of life for patients with serious medical conditions and life-limiting diseases. With expertise in clinical development and commercialization, they focus on addressing therapeutic needs in areas such as EPI (Exocrine Pancreatic Insufficiency), obesity, and PAH (Pulmonary Arterial Hypertension). Their portfolio includes PANCREAZE, an effective therapy for managing EPI, a condition characterized by a deficiency in pancreatic enzymes.
VIVUS operates in multiple regions, including the Americas, Europe, Asia Pacific, Africa, and the Middle East, with locations in the United States, Netherlands, Switzerland, and Canada. Committed to patient well-being, VIVUS strives to provide innovative solutions and contribute to the advancement of healthcare worldwide.
Generated from the website